SCHEMBL6535934

SCHEMBL6535934

O=Cc1ccccc1OCc1c(Cl)cccc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
HPGD P15428 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HTT P42858 1/20 0.59
KDM4E B2RXH2 2/20 0.54
POLB P06746 1/20 0.54
RECQL P46063 1/20 0.54
PTGDR2 Q9Y5Y4 1/20 0.50
TDP1 Q9NUW8 3/20 0.47
KMT2A Q03164 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PKM P14618 1/20 0.45
KCNH2 Q12809 1/20 0.44
PTGER1 P34995 2/20 0.44
PTGER4 P35408 2/20 0.44
PTGER3 P43115 2/20 0.44
PTGER2 P43116 2/20 0.44
CCNB2 O95067 1/20 0.44
CDK1 P06493 1/20 0.44
CDK4 P11802 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15619523 0.83 HPGD (0.66) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL1539547 0.83 CDK4 (0.45) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL28837460 0.83 HPGD (0.54) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
Ethylene SCHEMBL1539483 0.81 CDK4 (0.43) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
1,2-Dichlorobenzene SCHEMBL27565814 0.78 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL11614404 0.77 ALDH1A1 (0.70) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL8371569 0.77 KMT2A (0.66) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL28497259 0.77 HTT (0.56) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL6747871 0.76 KMT2A (0.60) ALDH1A1HPGDSMN1; SMN2HTTKDM4E
SCHEMBL7398748 0.76 ENPP2 (0.61) ALDH1A1HPGDSMN1; SMN2HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425015-A4 TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS BRISTOL MYERS SQUIBB CO (US) 2004-12-15 EP disclosed
US-6825208-B2 SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-11-30 US disclosed
EP-1425015-A2 TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-06-09 EP disclosed
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-12-04 US disclosed
WO-2003015715-A2 TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-02-27 WO disclosed
WO-2000053313-A2 LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES ARQULE, INC. (US) 2000-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents TFPI, TFPI2, SERPINC1 ALDH1A1 2602/4885HPGD 780/4885SMN1; SMN2 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.